Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
04:05pm, Wednesday, 06'th Nov 2024
Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month BLA submission for RGX-121 initia
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Monday, 04'th Nov 2024
ROCKVILLE, Md. , Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: UBS Global Healthcare Conference Fireside Chat:
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
03:38pm, Thursday, 31'st Oct 2024
Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
07:05am, Wednesday, 30'th Oct 2024
ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m.
97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314 Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile Well tol
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
07:05am, Friday, 18'th Oct 2024
ROCKVILLE, Md. , Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilat
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
04:05pm, Monday, 23'rd Sep 2024
ROCKVILLE, Md. , Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024.
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
07:05am, Tuesday, 17'th Sep 2024
Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programs Vit Vasista steps down following more than 15 years at the Company ROCKVILLE,
Goldman Sachs Recommends These 3 Growth Stocks As Strong Buys in September
08:29am, Monday, 09'th Sep 2024
Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS) has to be atop the list.
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
08:04am, Tuesday, 03'rd Sep 2024
- Data from pivotal dose level demonstrates long-term, sustained reductions in CSF levels of HS D2S6, a key biomarker of brain disease in MPS II - 80% of patients who received the pivotal dose dis
REGENXBIO to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 29'th Aug 2024
ROCKVILLE, Md. , Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthca
REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
07:05am, Tuesday, 27'th Aug 2024
ROCKVILLE, Md. , Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hu
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
07:05am, Thursday, 08'th Aug 2024
ROCKVILLE, Md. , Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C.
7 Biotech Stocks to Buy for Their Game-Changing Potential
06:00am, Thursday, 08'th Aug 2024
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
04:03pm, Tuesday, 06'th Aug 2024
Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the trea
